Anxiolytic-like effect of Pregabalin in mice tested in the dark/light box and the elevated plus maze test: effect on cannabinoid CB1 receptors
AlAbkal, F., Zaitone, S., Moustafa, Y. (2017). Anxiolytic-like effect of Pregabalin in mice tested in the dark/light box and the elevated plus maze test: effect on cannabinoid CB1 receptors. EKB Journal Management System, 1(1), 33-46. doi: 10.21608/rpbs.2018.5918
Faten A. AlAbkal; Sawsan Zaitone; Yasser M. Moustafa. "Anxiolytic-like effect of Pregabalin in mice tested in the dark/light box and the elevated plus maze test: effect on cannabinoid CB1 receptors". EKB Journal Management System, 1, 1, 2017, 33-46. doi: 10.21608/rpbs.2018.5918
AlAbkal, F., Zaitone, S., Moustafa, Y. (2017). 'Anxiolytic-like effect of Pregabalin in mice tested in the dark/light box and the elevated plus maze test: effect on cannabinoid CB1 receptors', EKB Journal Management System, 1(1), pp. 33-46. doi: 10.21608/rpbs.2018.5918
AlAbkal, F., Zaitone, S., Moustafa, Y. Anxiolytic-like effect of Pregabalin in mice tested in the dark/light box and the elevated plus maze test: effect on cannabinoid CB1 receptors. EKB Journal Management System, 2017; 1(1): 33-46. doi: 10.21608/rpbs.2018.5918

Anxiolytic-like effect of Pregabalin in mice tested in the dark/light box and the elevated plus maze test: effect on cannabinoid CB1 receptors

Records of Pharmaceutical and Biomedical Sciences
Article 5, Volume 1, Issue 1, March 2017, Page 33-46  XML PDF (790.8 K)
Document Type: Original Article
DOI: 10.21608/rpbs.2018.5918
View on SCiNiTO View on SCiNiTO
Authors
Faten A. AlAbkal email 1; Sawsan Zaitone2, 3; Yasser M. Moustafaorcid 2
1Ministry of Health, Kuwait City, Al-Kuwait
2Department of Pharmacology and Toxicology, Faculty of Pharmacy, Suez Canal University, Ismailia 41522, Egypt
3Department of Pharmacology and Toxicology, Faculty of Pharmacy, University of Tabuk, Kingdom of Saudi Arabia
Abstract
Pharmacotherapy of generalized anxiety disorders has been depended on benzodiazepines for many decades. However, the use of these compounds is restricted because of their adverse effects. Pregabalin is an anticonvulsant indicated as adjunctive therapy for treating adults’ partial seizures. It has shown some efficacy in randomized, placebo-controlled clinical trials aimed to treat generalized anxiety disorder. Mechanism of pharmacologic activity of Pregabalin was extensively studied and it was proven to acquire high-affinity binding to α2δ. The current study employed the dark/light box and the elevated plus maze. Male albino mice were allocated into groups: group i: mice received distilled water (16 ml/kg, p.o.), group ii: mice received diazepam (1 mg/kg, p.o.), group iii-iv: mice received a dose of Pregabalin (25 or 50 mg/kg, p.o.), group v: mice treated with rimonabant (1 mg/kg, i.p.) 30 min before a dose of Pregabalin (50 mg/kg), group vi: mice received rimonabant (1 mg/kg, i.p.) 30 min before a dose of distilled water (16 ml/kg, p.o.). Results indicated that Pregabalin (50 mg/kg) showed anxiolytic effect in the two paradigms, the dark/light transition box and the mouse elevated plus maze. Pretreatment with rimonabant diminished most of the anxiolytic effect of Pregabalin (50 mg/kg) as indicated by shorter time spent in white are in the dark/light box and shorter open arm time (%) compared to mice received Pregabalin.
Keywords
A2 receptors; anxiety; Dark-light box; Elevated plus maze; Pregabalin
Statistics
Article View: 301
PDF Download: 358